BackBiotech Acquisition Overview

Biotech Acquisition Total Current Liabilities

Track Biotech Acquisition's total current liabilities ($3.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$3.52M
↑ 881.11% YoYΔ $3.16M vs prior year quarter

Peer trimmed avg / median

Loading

Biotech Acquisition Total Current Liabilities History

Loading

Biotech Acquisition vs. peers: Total Current Liabilities Comparison

Loading

Biotech Acquisition Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Biotech Acquisition (BIOT) FAQ

As of the most recent data (September 2022), BIOT shows a total current liabilities of $3.5M. That compares with $360K in the prior-year period — up 881.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BIOT's total current liabilities is now $3.5M (was $360K) — a 881.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Biotech Acquisition is outperforming or lagging.

Tracking BIOT's total current liabilities over time shows whether Biotech Acquisition is scaling, shrinking, or reshaping that part of the business. The current reading is $3.5M That compares with $360K in the prior-year period — up 881.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Biotech Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $3.5M) with ownership activity and broader fundamentals.